Michael P Busch Selected Research

Donor Selection

1/2016	Extensive Genetic Diversity of HIV-1 in Incident and Prevalent Infections among Malaysian Blood Donors: Multiple Introductions of HIV-1 Genotypes from Highly Prevalent Countries.
12/2010	Enhanced classification of Chagas serologic results and epidemiologic characteristics of seropositive donors at three large blood centers in Brazil.
7/2010	A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME).
3/2006	West Nile virus infections projected from blood donor screening data, United States, 2003.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael P Busch Research Topics

Disease

99	Infections 06/2022 - 07/2002
34	Viremia 11/2020 - 03/2003
21	HIV Infections (HIV Infection) 10/2020 - 05/2002
15	COVID-19 10/2022 - 01/2020
12	West Nile Fever 01/2016 - 08/2005
7	Hemolysis 11/2022 - 01/2019
7	Zika Virus Infection 01/2022 - 01/2017
7	Transfusion-Related Acute Lung Injury 10/2011 - 02/2009
5	Persistent Infection 01/2016 - 10/2007
5	Wounds and Injuries (Trauma) 12/2012 - 10/2004
4	Dengue (Dengue Fever) 01/2022 - 01/2016
4	Inflammation (Inflammations) 12/2021 - 08/2013
4	Iron Deficiencies 01/2021 - 02/2012
3	Reinfection 02/2022 - 02/2013
3	Chagas Disease (American Trypanosomiasis) 02/2021 - 12/2010
3	Flavivirus Infections 01/2021 - 09/2005
3	HIV Seropositivity 12/2016 - 03/2006
3	Hepatitis B 03/2014 - 08/2004
3	Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease) 09/2005 - 09/2004
2	Glucosephosphate Dehydrogenase Deficiency 11/2022 - 01/2021
2	Convalescence 02/2022 - 01/2021
2	Neoplasms (Cancer) 01/2022 - 01/2013
2	Hepatitis C 01/2022 - 09/2011
2	Virus Diseases (Viral Diseases) 01/2022 - 11/2003
2	Cough 07/2021 - 03/2021
2	Fever (Fevers) 07/2021 - 03/2021
2	Restless Legs Syndrome (Restless Legs) 01/2021 - 01/2019
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020 - 11/2017
2	Infertility (Sterility) 01/2020 - 07/2014
2	Breakthrough Infections 01/2019 - 03/2014
2	Parasitemia 12/2018 - 11/2018
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2018 - 11/2016
2	Asymptomatic Infections 06/2016 - 07/2003
2	Acquired Immunodeficiency Syndrome (AIDS) 12/2012 - 07/2003
2	Chronic Hepatitis C 07/2012 - 07/2010
2	Hepatitis 09/2007 - 03/2003
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2022
1	Parasitic Diseases (Parasitic Disease) 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Thalassemia 01/2022
1	Chagas Cardiomyopathy 11/2021
1	Drug-Related Side Effects and Adverse Reactions 02/2021
1	Severe Dengue 01/2021

Drug/Important Bio-Agent (IBA)

41	RNA (Ribonucleic Acid)IBA 01/2022 - 05/2002
29	AntibodiesIBA 10/2022 - 07/2006
20	AntigensIBA 02/2021 - 05/2002
19	Immunoglobulin G (IgG)IBA 02/2022 - 09/2005
19	Nucleic AcidsIBA 01/2022 - 04/2003
18	VaccinesIBA 01/2022 - 11/2006
17	Immunoglobulin M (IgM)IBA 01/2021 - 08/2005
15	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 05/2002
12	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2004
12	EnzymesIBA 01/2021 - 05/2002
12	N-acetyltalosaminuronic acid (NAT)IBA 10/2020 - 08/2003
9	Neutralizing AntibodiesIBA 01/2022 - 01/2020
8	Pharmaceutical PreparationsIBA 07/2012 - 07/2002
7	Biomarkers (Surrogate Marker)IBA 01/2019 - 11/2003
5	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2012
5	IronIBA 01/2021 - 02/2012
5	InterferonsIBA 07/2020 - 10/2008
4	Biological ProductsIBA 01/2022 - 07/2005
4	Peptides (Polypeptides)IBA 01/2022 - 12/2003
4	CytokinesIBA 07/2020 - 08/2006
4	Interleukin-10 (Interleukin 10)IBA 03/2014 - 08/2006
4	HLA Antigens (Human Leukocyte Antigens)IBA 04/2011 - 02/2009
4	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2006 - 06/2003
3	HIV AntibodiesIBA 09/2019 - 01/2010
3	AIDS VaccinesIBA 01/2019 - 11/2006
3	InterleukinsIBA 03/2014 - 08/2012
2	Glutathione (Reduced Glutathione)IBA 01/2022 - 01/2021
2	amotosalenIBA 01/2022 - 01/2022
2	Oxygen (Dioxygen)IBA 07/2021 - 03/2021
2	benzonidazole (benznidazole)IBA 02/2021 - 11/2018
2	NucleoproteinsIBA 01/2021 - 05/2020
2	Interferon LambdaIBA 12/2020 - 11/2020
2	Viral RNAIBA 12/2020 - 04/2009
2	Hormones (Hormone)IBA 01/2019 - 01/2019
2	Immunoglobulins (Immunoglobulin)IBA 01/2016 - 09/2011
2	Interleukin-13IBA 12/2012 - 08/2006
2	ChemokinesIBA 09/2011 - 10/2008
2	HLA-DR Antigens (HLA-DR)IBA 04/2011 - 01/2011
1	Hemoglobins (Hemoglobin)IBA 11/2022
1	BilirubinIBA 11/2022
1	(N,N- bis(2- chloroethyl))- 2- aminoethyl- 3- ((acridin- 9- yl)amino)propionateIBA 01/2022
1	Amino Acids FDA Link 01/2022
1	Oxidants (Oxidizing Agents)IBA 01/2021
1	Nucleocapsid ProteinsIBA 01/2021
1	Carrier Proteins (Binding Protein)IBA 01/2021
1	IsotopesIBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	SolutionsIBA 01/2021
1	Ion Channels (Ion Channel)IBA 01/2021

Therapy/Procedure

16	Therapeutics 11/2021 - 07/2002
8	Blood Transfusion (Blood Transfusions) 06/2022 - 10/2004
6	Art Therapy 11/2020 - 03/2006
6	Highly Active Antiretroviral Therapy (HAART) 03/2014 - 07/2003
4	Blood Component Removal (Apheresis) 01/2020 - 02/2008
4	Donor Selection 01/2016 - 03/2006
3	Immunotherapy 01/2022 - 01/2016
1	Ambulatory Care (Outpatient Care) 11/2021